These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
594 related articles for article (PubMed ID: 28471952)
21. The clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis. Wen Y; Chen Y; Duan X; Zhu W; Cai C; Deng T; Zeng G Clin Exp Med; 2019 Nov; 19(4):407-416. PubMed ID: 31407099 [TBL] [Abstract][Full Text] [Related]
22. Role of programmed cell death ligand-1 expression on prognostic and overall survival of breast cancer: A systematic review and meta-analysis. Li S; Chen L; Jiang J Medicine (Baltimore); 2019 Apr; 98(16):e15201. PubMed ID: 31008945 [TBL] [Abstract][Full Text] [Related]
23. Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis. Zhang C; Yang Q Front Oncol; 2020; 10():572203. PubMed ID: 33634012 [TBL] [Abstract][Full Text] [Related]
24. Clinicopathological and prognostic significance of PD-L1 expression in sarcoma: A systematic review and meta-analysis. Zheng C; You W; Wan P; Jiang X; Chen J; Zheng Y; Li W; Tan J; Zhang S Medicine (Baltimore); 2018 Jun; 97(25):e11004. PubMed ID: 29923984 [TBL] [Abstract][Full Text] [Related]
25. The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: a meta-analysis of 10 studies with 1,901 patients. Zhang M; Dong Y; Liu H; Wang Y; Zhao S; Xuan Q; Wang Y; Zhang Q Sci Rep; 2016 Nov; 6():37933. PubMed ID: 27892511 [TBL] [Abstract][Full Text] [Related]
26. Prognostic value of programmed cell death ligand 1 expression in patients with intrahepatic cholangiocarcinoma: a meta-analysis. Xian F; Ren D; Bie J; Xu G Front Immunol; 2023; 14():1119168. PubMed ID: 37138876 [TBL] [Abstract][Full Text] [Related]
27. The prevalence and prognostic and clinicopathological value of PD-L1 and PD-L2 in renal cell carcinoma patients: a systematic review and meta-analysis involving 3,389 patients. Lu Y; Song Y; Xu Y; Ou N; Liang Z; Hu R; Zhang W; Kang J; Wang X; Liu L; Yang Y; Liu X Transl Androl Urol; 2020 Apr; 9(2):367-381. PubMed ID: 32420142 [TBL] [Abstract][Full Text] [Related]
28. Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma. Jung HI; Jeong D; Ji S; Ahn TS; Bae SH; Chin S; Chung JC; Kim HC; Lee MS; Baek MJ Cancer Res Treat; 2017 Jan; 49(1):246-254. PubMed ID: 27456947 [TBL] [Abstract][Full Text] [Related]
29. Soluble PD-L1 as a Prognostic Factor for Immunotherapy Treatment in Solid Tumors: Systematic Review and Meta-Analysis. Scirocchi F; Strigari L; Di Filippo A; Napoletano C; Pace A; Rahimi H; Botticelli A; Rughetti A; Nuti M; Zizzari IG Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430974 [TBL] [Abstract][Full Text] [Related]
30. Prognostic and Clinicopathological Significance of PD-L1 in Patients with Cholangiocarcinoma: A Meta-Analysis. Xie Q; Wang L; Zheng S Dis Markers; 2020; 2020():1817931. PubMed ID: 32724483 [TBL] [Abstract][Full Text] [Related]
31. Correlation between PD-L1 expression ON CTCs and prognosis of patients with cancer: a systematic review and meta-analysis. Kong D; Zhang W; Yang Z; Li G; Cheng S; Zhang K; Feng L Oncoimmunology; 2021 Jun; 10(1):1938476. PubMed ID: 34211802 [TBL] [Abstract][Full Text] [Related]
32. Relationship of programmed death ligand-1 expression with clinicopathological features and prognosis in patients with oral squamous cell carcinoma: A meta-analysis. He J; Chen XF; Xu MG; Zhao J Arch Oral Biol; 2020 Jun; 114():104717. PubMed ID: 32344357 [TBL] [Abstract][Full Text] [Related]
33. Expression of PD-L1 and prognosis in breast cancer: a meta-analysis. Zhang M; Sun H; Zhao S; Wang Y; Pu H; Wang Y; Zhang Q Oncotarget; 2017 May; 8(19):31347-31354. PubMed ID: 28430626 [TBL] [Abstract][Full Text] [Related]
34. The prognostic role of programmed cell death-ligand 1 expression in non-small cell lung cancer patients: An updated meta-analysis. Ma G; Deng Y; Jiang H; Li W; Wu Q; Zhou Q Clin Chim Acta; 2018 Jul; 482():101-107. PubMed ID: 29614306 [TBL] [Abstract][Full Text] [Related]
35. Prognostic value of programmed cell death ligand-1 expression in ovarian cancer: an updated meta-analysis. Piao J; Lim HJ; Lee M Obstet Gynecol Sci; 2020 May; 63(3):346-356. PubMed ID: 32489980 [TBL] [Abstract][Full Text] [Related]
36. Effect of CD274 (PD-L1) overexpression on survival outcomes in 10 specific cancers: a systematic review and meta-analysis. Park JH; Luchini C; Nottegar A; Tizaoui K; Koyanagi A; Ogino S; Shin JI; Lim BJ; Smith L J Clin Pathol; 2023 Jul; 76(7):450-456. PubMed ID: 37130750 [TBL] [Abstract][Full Text] [Related]
37. Prognostic role of programmed death-ligand 1 expression in patients with biliary tract cancer: a meta-analysis. Lei C; Peng X; Gong X; Fan Y; Wu S; Liu N; Li L; Huang J; Zheng G; Long Z Aging (Albany NY); 2019 Dec; 11(24):12568-12580. PubMed ID: 31881008 [TBL] [Abstract][Full Text] [Related]
38. Prognostic and clinicopathological significance of PD-L1 in patients with renal cell carcinoma: a meta-analysis based on 1863 individuals. Wang Z; Peng S; Xie H; Guo L; Cai Q; Shang Z; Jiang N; Niu Y Clin Exp Med; 2018 May; 18(2):165-175. PubMed ID: 29362922 [TBL] [Abstract][Full Text] [Related]
39. PD-L1 and Survival in Solid Tumors: A Meta-Analysis. Wu P; Wu D; Li L; Chai Y; Huang J PLoS One; 2015; 10(6):e0131403. PubMed ID: 26114883 [TBL] [Abstract][Full Text] [Related]
40. Prognostic Significance of the Metabolic Marker Hexokinase-2 in Various Solid Tumors: A Meta-Analysis. Liu Y; Wu K; Shi L; Xiang F; Tao K; Wang G PLoS One; 2016; 11(11):e0166230. PubMed ID: 27824926 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]